JPM CBRN MEDICAL COVID-19 DIAGNOSTIC CAPABILITY: NGDS 1 (BIOFIRE FILMARRAY 2.0G)

The JPM CBRN Medical aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation's biodefense response capability.

OVERVIEW

The JPEO-CBRND's Next Generation Diagnostics System 1 (NGDS 1) protects the Joint Force through the identification of biological hazards, providing information that facilitates the delivery of appropriate medical countermeasures or implementation of physical protection measures, therefore minimizing the debilitating effects of exposure. The NGDS 1 is a commercial analyzer (BioFire FilmArray 2.0), with DOD-developed panels, that uses polymerase chain reaction (PCR) technology to rapidly identify biological pathogens in clinical and environmental samples. A COVID-19-specific diagnostic test was developed by BioFire Defense, LLC and granted an Emergency Use Authorization (EUA) by the FDA on March 23, 2020, permitting its immediate use. The diagnostic system and tests are designed to be easy-to-use, be positioned within patient care facilities, and deliver results within one hour.

WHY DOES DOD NEED THIS?

- Significantly increases the DOD's diagnostics capacity and capability, as demand for COVID-19 testing continues to rise within the Joint Force
- Allows for the rapid diagnosis of COVID-19 cases and may prevent virus spread among DOD personnel who often operate in close quarters; avoiding large numbers of infected service members preserves readiness and strengthens national security
- Availability of diagnostic equipment and tests in DOD Medical Treatment Facilities provides the capability to care for active duty service members, beneficiaries, and retirees, lessening the burden on the civilian health care system

WHY THE JPEO-CBRND?

- Focal point for development, acquisition, fielding, and life cycle support of chemical and biological defense equipment and FDA-approved medical countermeasures, with a proven track record of providing essential diagnostic capability to the Joint Force
- Has obligated and managed funding for the development of diagnostic systems and tests that DOD relies on to quickly and accurately diagnose a variety of chemical, biological, and endemic disease threats since 2012
- Leveraged an existing contract with industry partner BioFire Defense, LLC to rapidly deliver a diagnostic solution to test for COVID-19



"GIVEN THE COVID-19 TESTING AVAILABILITY CHALLENGES WE'RE SEEING, HAVING THIS EUA MEANS DOD CAN USE THE FILMARRAY®, WHICH IS THE DEPARTMENT'S BIOLOGICAL DIAGNOSTIC CAPABILITY, TO TEST SERVICE MEMBERS ACROSS THE GLOBE. THE TEST WILL ALLOW US TO DIAGNOSE COVID-19 INFECTIONS QUICKLY AND CONFIDENTLY AND THEN WORK TO GET THOSE SOLDIERS, SAILORS, AIRMEN, AND MARINES HEALTHY AGAIN AS QUICKLY AS POSSIBLE." - DR. JASON ROOS

Government Partners

- U.S. Food and Drug Administration (FDA)
- Department of Defense (DOD)
- United States Army

Industry Partners

- BioFire Defense, LLC

JOINT PRODUCT MANAGER CBRN MEDICAL | 301-619-7400 | USARMY.DETRICK.DOD-JPEO-CBRND.LIST.COMMUNICATIONS@MAIL.MIL